Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.

"bcg patients (n=12) received six instillations of reconstituted oncotice (2-8x10 8 cfu) 10 1136/jitc-2023-008020 supp1 supplementary data 10 1136/jitc-2023-008020 supp2 supplementary data an ae score to quantify the number and intensity of the aes observed in ty21a-treated patients was defined as the sum of the number of aes x their intensity (ie 1 for common terminology criteria for advserse events (ctcae) grade 1 or 2 for ctcae grade 2) at visits1 to 4 or 6."

"Competing interests: DN-H, SD-P and PJ are inventors on patent PCT/EP2014/059392 “Salmonella strains for use in the treatment and/or prevention of cancer”. The other authors declare no potential conflicts of interest."

"Contributors: Study concept and design: LD, IL and DN-H. Acquisition of data: VC, SB, MFC, SD-P, SN, LP and AKS. Analysis and interpretation of data: LD, IL, VC and DN-H. Drafting of the manuscript: LD, IL and DN-H. Critical revision of the manuscript for important intellectual content: IL, VC, PB, FC, SB, MFC, SD-P, SN, PJ and BR. Statistical analysis: LD and DN-H. Obtaining funding: PJ and DN-H. Administrative, technical, or material support: LD, IL, VC, PB, FC, S-CR-D, FD, AM, SB, CT-P, MFC, SD-P, SN, LP, AKS, PJ and BR. Supervision: DN-H. Guarantor: DN-H."